Skip to main content
Clinical Trials/ISRCTN83474650
ISRCTN83474650
Completed
Not Applicable

Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention (PCI) in patients pretreated with 600 mg clopidogrel, rationale and design of the RISK-PCI study

Clinical Center of Serbia (Serbia)0 sites1,750 target enrollmentSeptember 30, 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Clinical Center of Serbia (Serbia)
Enrollment
1750
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 30, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Clinical Center of Serbia (Serbia)

Eligibility Criteria

Inclusion Criteria

  • 1\. Both males and females, 18 years of age or older
  • 2\. Chest discomfort persisting for more than 20 minutes
  • 3\. Presentation within 12 hours after the onset of symptoms
  • 4\. ST elevation in two contiguous leads of at least 0\.2 mV in leads V2?V3 and/or of at least \>0\.1 mV in other leads, or new bundle branch block
  • 5\. Cardiac troponin exceeding upper reference limit at admission and/or 24 hours later

Exclusion Criteria

  • 1\. Refusal to give consent for invasive treatment
  • 2\. Contraindications for dual antiplatelet therapy or contrast agents (active or recent internal bleeding, history of bleeding after non\-steroid anti\-inflammatory agents, known bleeding diathesis, allergy, intracerebral mass or aneurysm, platelet count of \<100,000/mm^3
  • 3\. Cardiogenic shock at admission
  • 4\. Noncardiac conditions that could limit life expectancy to less than 1 year or that might interfere with compliance with the protocol (active cancer, significant liver or renal disease \[creatinine clearance \<30 ml/min], significant psychiatric disorders)
  • 5\. Planned elective surgery necessitating interruption of treatment with thienopyridines during the first 6 months after enrolment

Outcomes

Primary Outcomes

Not specified

Similar Trials